---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-142093"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-26T00:12:08.838419+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Arrowhead appoints Victoria Vakiener to board as independent director

## Summary
- Victoria Vakiener appointed effective May 2, 2022, as independent director.
- She has extensive biotech/commercial experience; former CCO of Epizyme and 20+ years at J&J.
- Granted 17,181 restricted stock units vesting over three years as standard director comp.
- Ms. Vakiener also serves on board of Chimerix, a clinical-stage biopharma company.

## SEC filing metadata
- accession: 0001193125-22-142093
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000119312522142093/0001193125-22-142093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000119312522142093/d342404d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-142093
- JSON: https://secwatch.observer/filing/0001193125-22-142093.json
- Plain text: https://secwatch.observer/filing/0001193125-22-142093.txt

## Key facts
- Executive change
  Victoria Vakiener was appointed as Director at ARROWHEAD PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Director
  source text: the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”) appointed Victoria Vakiener as an independent director of the Company effective May 2, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/879407/000119312522142093/0001193125-22-142093-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.